Safety Outcomes / Cancer

(C-225) Adverse events of treatment and characteristics of patients with multiple myeloma: a Brazilian historical cohort study

(C-209) Antidepressant Use and Colonrectal Cancer Risk: A Systematic Review and Meta-Analysis

(C-210) Association Between 5alpha-Reductase Inhibitors and Incident Cancer in Patients with Benign Prostatic Hyperplasia: Evidence from a Matched Cohort Study

(C-221) Atrial Fibrillation and Bleeding in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) on Ibrutinib vs Acalabrutinib: Role of Age, Frailty, and Anticoagulants

(C-223) Chimeric Antigen Receptor Therapy (CAR T) Therapy and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): A Systematic Review and Meta-analysis

(C-216) Diuretics are associated with rates of basal and squamous cell carcinomas of the skin in the U.S. Medicare population with hypertension

(C-226) Efficacy and Safety of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.

(C-208) Examining valproate’s potential anticancer effect among patients with bipolar disorder: a territory-wide active-comparator new user study spanning two decades

(C-220) Global Feasibility Assessment of Real-World Databases for Long-Term Safety of Vitiligo Treatments

(C-213) Immune related kidney toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers

(C-212) Immune related liver toxicity, management, and outcomes in ICI treated patients with advanced or metastatic cancers

(C-211) Immune-mediated adverse events in patients with high-risk melanoma receiving immune checkpoint inhibitors in adjuvant and first-line treatment settings: a real-world analysis

(C-224) Impact of Systemic Corticosteroid Use on Survival Outcomes in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study

(C-207) Implementing robust machine learning pipelines with real-world data: identifying predictors of immune mediated adverse events among patients with advanced melanoma treated with immune checkpoint inhibitors

(C-217) Incidence of Cataract Among Patients Exposed to FGFR Inhibitors in the Real-World

(C-222) Incidence of second primary T-cell non-Hodgkin lymphoma among multiple myeloma patients: evidence from real-world data

(C-215) Methodological Approaches to Capture Real-World Adverse Events (AEs) of first-line (1L) Systemic Treatments in Electronic Health Records (EHRs) in a cohort of Patients With Locally Advanced/Metastatic Urothelial Cancer (la/mUC)

(C-219) Quality Evaluation of Previous Studies on Glucocorticoid Use and Risk of Site-Specific Cancers: A Systematic Review

(C-206) Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two years of Experience from the CorEvitas AD Registry

(C-214) Second Primary Malignancy in Patients with Multiple Myeloma Receiving Chimeric Antigen Receptor T-Cell Therapy and Other Systemic Anticancer Therapy: A Comparative Study Using a Real-World Database

(C-218) Use of Systemic Glucocorticoids and Risk of Prostate Adenocarcinoma: Evidence From a Danish Population-Based Case-Control Study